All In Biotech

Drug Trial Radar · NCT04666610

A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

A Randomized, Dose-Finding and Confirmatory, Double-Blind, Placebo-Controlled, Parallel-Group Multicenter Study With a 2 Stage Adaptive Design and Randomized Withdrawal to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 154 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

154

Actual

Start

Jul 29, 2021

Primary completion

Jul 7, 2026

Study completion Jul 7, 2026

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Dec 14, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 25 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to test the efficacy, safety and tolerability of brivaracetam monotherapy in study participants 2 to 25 years of age inclusive with childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE).

Conditions

  • Childhood Absence Epilepsy
  • Juvenile Absence Epilepsy

Interventions

  • BrivaracetamDrug

    * Pharmaceutical form: Oral solution * Route of administration: Oral use Brivaracetam (oral solution \[10 mg/ml, 5 mg/ml or 2.5 mg/ml\] will be administered.

  • PlaceboOther

    Subjects will receive placebo at pre-specified time-points to maintain the blinding.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants who met the criteria for absence seizure freedom within 4 days prior to or during the 24-hour ambulatory electroencephalogram (EEG) at Day 14Time frame: Day 14

Locations

35 sites in 7 countries. Site status is shown where the registry gives one.

  • N01269 115

    Birmingham, Alabama

  • N01269 105

    Orange, California

  • N01269 116

    Denver, Colorado

  • N01269 111

    Miami, Florida

  • N01269 101

    Tampa, Florida

  • N01269 104

    Winter Park, Florida

  • N01269 110

    Augusta, Georgia

  • N01269 100

    New Brunswick, New Jersey

  • N01269 109

    Winston-Salem, North Carolina

  • N01269 106

    Philadelphia, Pennsylvania

  • N01269 400

    Tbilisi, Georgia

  • N01269 401

    Tbilisi, Georgia

  • N01269 402

    Tbilisi, Georgia

  • N01269 403

    Tbilisi, Georgia

  • N01269 405

    Tbilisi, Georgia

  • N01269 323

    Messina, Italy

  • N01269 321

    Milan, Italy

  • N01269 324

    Milan, Italy

  • N01269 320

    Pavia, Italy

  • N01269 322

    Roma, Italy

  • N01269 325

    Roma, Italy

  • N01269 326

    Verona, Italy

  • N01269 562

    Bucharest, Romania

  • N01269 563

    Bucharest, Romania

  • N01269 560

    Iași, Romania

  • N01269 561

    Timişoara, Judeţ Timiş, Romania

  • N01269 632

    Bardejov, Slovakia

  • N01269 630

    Dubnica nad Váhom, Slovakia

  • N01269 631

    Nové Zámky, Slovakia

  • N01269 354

    Terrassa, Spain

  • N01269 600

    Dnipro, Ukraine

  • N01269 601

    Dnipro, Ukraine

  • N01269 604

    Kharkiv, Ukraine

  • N01269 607

    Uzhhorod, Ukraine

  • N01269 602

    Vinnytsia, Ukraine

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.